From NASDAQ:

Eli Lilly and Meta Platforms are two very different companies, both classified as giants in their individual industries. Meta Platforms once held the title of being a trillion-dollar company in 2021, but now is on the way to reclaiming that position with a current market cap of $962 billion. Meanwhile, Eli Lilly stands at a market cap of about $610 billion, with the potential to reach a trillion-dollar valuation.

Eli Lilly has experienced significant growth since 2022, due to achievements like the approval of their innovative diabetes medicine called Mounjaro and the label expansion of obesity drug Zepbound. With several other successful medicines being introduced to the market, as well as others in the pipeline, the company is expected to outperform the market through 2030.

While Meta Platforms took a hit during the pandemic, it has bounced back with recovering opportunities for advertising, short-form videos on Facebook and Instagram, and advancements in artificial intelligence. The company has strong prospects for the future, signaling the potential to outperform the market through 2030.

At its current valuation, Eli Lilly will need an annual growth rate of about 8.6% to become a trillion-dollar stock in the next six years, which seems achievable. Meta Platforms, even though likely to rejoin the trillion-dollar rank sooner, may not outperform Eli Lilly through 2030. Nonetheless, both companies are still seen as good investments.

The Motley Fool has identified 10 best stocks for investors to buy now, where Eli Lilly is not one of them. The company’s Stock Advisor service provides investors with a blueprint for success. However, Randi Zuckerberg, a former director of market development and spokeswoman for Facebook, and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool’s board of directors. Prosper Junior Bakiny has positions in Meta Platforms, and The Motley Fool has positions in and recommends Meta Platforms.



Read more: Will Eli Lilly Be Worth More Than Meta Platforms by 2030?